Exelixis to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025Business Wire • 01/06/25
Exelixis Stock Surges 50% in a Year: Is There Room for Further Growth?Zacks Investment Research • 01/06/25
Exelixis (EXEL) Up 10.8% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 11/28/24
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in DecemberBusiness Wire • 11/27/24
ODAC to Discuss Exelixis' Application for Cabometyx Label ExpansionZacks Investment Research • 11/27/24
Exelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine TumorsBusiness Wire • 11/26/24
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in NovemberBusiness Wire • 11/07/24
Exelixis (EXEL) Reliance on International Sales: What Investors Need to KnowZacks Investment Research • 11/04/24
Exelixis: Cabometyx Drives Revenue While Zanzalintinib Emerges As Future Growth EngineSeeking Alpha • 10/31/24
Exelixis (EXEL) Reports Q3 Earnings: What Key Metrics Have to SayZacks Investment Research • 10/29/24